Curium Eyes $7B Lantheus Takeover in Nuclear Medicine Push
Curium is in talks to acquire Lantheus Holdings for roughly $7 billion, a deal that would reshape the nuclear medicine space.
A blockbuster deal may be brewing in the radiopharmaceutical sector. Curium, a privately held nuclear medicine company, is reportedly in active talks to acquire Lantheus Holdings in a transaction valued at approximately $7 billion, according to Bloomberg. If it closes, this would be one of the biggest moves in the fast-growing world of targeted radioligand therapies.
Lantheus has carved out a dominant position in diagnostic imaging, particularly with its PYLARIFY PET imaging agent used in prostate cancer detection. That commercial success has made it a highly attractive acquisition target, and a $7 billion price tag reflects just how competitive the nuclear medicine space has become as Big Pharma and private players race to own the supply chain.
Read more Bitcoin Faces Inflation Data and Iran War Risk This Week →
For traders, this is the kind of news that moves fast. Lantheus shares have already been a momentum name — any confirmed deal or bidding war could send the stock sharply higher from current levels. Watch for competing bids too. When a strategic asset this well-positioned hits the tape, other players rarely sit on the sidelines.
Curium is backed by private equity and has been aggressively expanding its radiopharmaceutical manufacturing footprint across Europe and North America. Absorbing Lantheus would give it a major commercial engine in the U.S. market and a pipeline of next-generation diagnostic and therapeutic compounds that few competitors can match.
Nothing is signed yet, and deals at this size can fall apart. But the direction of travel in nuclear medicine M&A is unmistakable — assets are getting scooped up fast, and Lantheus has long been considered a crown jewel. Continue reading at SeekingAlpha.
